CLRB
Cellectar
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CLRB
Cellectar Biosciences, Inc.
A late-stage biopharmaceutical company focused on targeted treatments for cancer
100 Campus Drive, Florham Park, New Jersey 07932
--
Cellectar Biosciences, Inc., formerly known as Novelos Therapeutics, Inc., was founded in Delaware in June 1996. On February 11, 2014, the company changed its name to its current name. The company is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of cancer therapies. The company's core objective is to utilize proprietary phospholipid ether drug conjugate delivery platforms to develop PDCs that are designed to specifically target cancer cells and provide better efficacy and better safety due to fewer off-target effects.
Earnings Call
Q1/2025
Estimate EPS-0.16
Actual EPS-0.14
Estimate Revenue--
Actual Revenue0
Cellectar Biosciences' Q1 2025: Key Contradictions in Trial Design, Market Strategy, and Response Rates
May 20,2025 12:44
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CLRB has released its 2025 Q1 earnings. EPS was reported at -0.14, versus the expected -0.16, beating expectations. The chart below visualizes how CLRB has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
